Radiochemotherapy with paclitaxel for recurrent previously irradiated squamous cell carcinoma of the head and neck

Dirk Rades, Daniel Seidl, Barbara Wollenberg, Steven E. Schild, Samer G. Hakim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aim: Locoregional recurrences of squamous cell carcinoma of the head and neck (SCCHN) are difficult to treat. If radiotherapy was included in the primary treatment, another curative course of radiotherapy incurs substantial risk of complications. Results of re-irradiation can be improved by concurrent chemotherapy. Patients and Methods: Radiotherapy with low doses per fraction twice daily and paclitaxel were applied in four patients with recurrent SCCHN. Radiotherapy was administered with doses of 30-36 Gy and doses per fraction of 1.5 Gy twice daily. Concurrent chemotherapy consisted of 20-25 mg/m2 paclitaxel twice per week. Overall 1-year locoregional control following re-irradiation was 25%. One-year locoregional control rates were 75% inside the re-irradiated region and 50% outside the re-irradiated region. Distant metastases did not occur. One-year overall survival following re-irradiation was 75%. Toxicity did not exceed grade 2. Conclusion: Re-irradiation plus concurrent paclitaxel appeared well-tolerated and resulted in promising outcomes.

Original languageEnglish (US)
Pages (from-to)5463-5468
Number of pages6
JournalAnticancer Research
Volume36
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Chemoradiotherapy
Paclitaxel
Radiotherapy
Drug Therapy
Neoplasm Metastasis
Recurrence
Survival
Carcinoma, squamous cell of head and neck
Re-Irradiation
Therapeutics

Keywords

  • Locoregional recurrence
  • Paclitaxel
  • Radiochemotherapy
  • Re-irradiation
  • Squamous cell carcinoma of the head and neck

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Radiochemotherapy with paclitaxel for recurrent previously irradiated squamous cell carcinoma of the head and neck. / Rades, Dirk; Seidl, Daniel; Wollenberg, Barbara; Schild, Steven E.; Hakim, Samer G.

In: Anticancer Research, Vol. 36, No. 10, 01.10.2016, p. 5463-5468.

Research output: Contribution to journalArticle

Rades, Dirk ; Seidl, Daniel ; Wollenberg, Barbara ; Schild, Steven E. ; Hakim, Samer G. / Radiochemotherapy with paclitaxel for recurrent previously irradiated squamous cell carcinoma of the head and neck. In: Anticancer Research. 2016 ; Vol. 36, No. 10. pp. 5463-5468.
@article{897940e1d56f4fe98d15a40dcb35140d,
title = "Radiochemotherapy with paclitaxel for recurrent previously irradiated squamous cell carcinoma of the head and neck",
abstract = "Background/Aim: Locoregional recurrences of squamous cell carcinoma of the head and neck (SCCHN) are difficult to treat. If radiotherapy was included in the primary treatment, another curative course of radiotherapy incurs substantial risk of complications. Results of re-irradiation can be improved by concurrent chemotherapy. Patients and Methods: Radiotherapy with low doses per fraction twice daily and paclitaxel were applied in four patients with recurrent SCCHN. Radiotherapy was administered with doses of 30-36 Gy and doses per fraction of 1.5 Gy twice daily. Concurrent chemotherapy consisted of 20-25 mg/m2 paclitaxel twice per week. Overall 1-year locoregional control following re-irradiation was 25{\%}. One-year locoregional control rates were 75{\%} inside the re-irradiated region and 50{\%} outside the re-irradiated region. Distant metastases did not occur. One-year overall survival following re-irradiation was 75{\%}. Toxicity did not exceed grade 2. Conclusion: Re-irradiation plus concurrent paclitaxel appeared well-tolerated and resulted in promising outcomes.",
keywords = "Locoregional recurrence, Paclitaxel, Radiochemotherapy, Re-irradiation, Squamous cell carcinoma of the head and neck",
author = "Dirk Rades and Daniel Seidl and Barbara Wollenberg and Schild, {Steven E.} and Hakim, {Samer G.}",
year = "2016",
month = "10",
day = "1",
doi = "10.21873/anticanres.11126",
language = "English (US)",
volume = "36",
pages = "5463--5468",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Radiochemotherapy with paclitaxel for recurrent previously irradiated squamous cell carcinoma of the head and neck

AU - Rades, Dirk

AU - Seidl, Daniel

AU - Wollenberg, Barbara

AU - Schild, Steven E.

AU - Hakim, Samer G.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background/Aim: Locoregional recurrences of squamous cell carcinoma of the head and neck (SCCHN) are difficult to treat. If radiotherapy was included in the primary treatment, another curative course of radiotherapy incurs substantial risk of complications. Results of re-irradiation can be improved by concurrent chemotherapy. Patients and Methods: Radiotherapy with low doses per fraction twice daily and paclitaxel were applied in four patients with recurrent SCCHN. Radiotherapy was administered with doses of 30-36 Gy and doses per fraction of 1.5 Gy twice daily. Concurrent chemotherapy consisted of 20-25 mg/m2 paclitaxel twice per week. Overall 1-year locoregional control following re-irradiation was 25%. One-year locoregional control rates were 75% inside the re-irradiated region and 50% outside the re-irradiated region. Distant metastases did not occur. One-year overall survival following re-irradiation was 75%. Toxicity did not exceed grade 2. Conclusion: Re-irradiation plus concurrent paclitaxel appeared well-tolerated and resulted in promising outcomes.

AB - Background/Aim: Locoregional recurrences of squamous cell carcinoma of the head and neck (SCCHN) are difficult to treat. If radiotherapy was included in the primary treatment, another curative course of radiotherapy incurs substantial risk of complications. Results of re-irradiation can be improved by concurrent chemotherapy. Patients and Methods: Radiotherapy with low doses per fraction twice daily and paclitaxel were applied in four patients with recurrent SCCHN. Radiotherapy was administered with doses of 30-36 Gy and doses per fraction of 1.5 Gy twice daily. Concurrent chemotherapy consisted of 20-25 mg/m2 paclitaxel twice per week. Overall 1-year locoregional control following re-irradiation was 25%. One-year locoregional control rates were 75% inside the re-irradiated region and 50% outside the re-irradiated region. Distant metastases did not occur. One-year overall survival following re-irradiation was 75%. Toxicity did not exceed grade 2. Conclusion: Re-irradiation plus concurrent paclitaxel appeared well-tolerated and resulted in promising outcomes.

KW - Locoregional recurrence

KW - Paclitaxel

KW - Radiochemotherapy

KW - Re-irradiation

KW - Squamous cell carcinoma of the head and neck

UR - http://www.scopus.com/inward/record.url?scp=84991755869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991755869&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11126

DO - 10.21873/anticanres.11126

M3 - Article

C2 - 27798916

AN - SCOPUS:84991755869

VL - 36

SP - 5463

EP - 5468

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -